Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29528
Title: Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis
Authors: SAMPAIO-BARROS, Percival D.ANDRADE, Danieli C. O.SEGURO, Luciana C. P.PASOTO, Sandra G.VIANA, Vilma S. T.RIBEIRO, Ana C. M.AIKAWA, Nadia E.TIMENETSKY, Maria do Carmo S.PRECIOSO, Alexander R.SILVA, Clovis A.BONFA, Eloisa
Citation: RHEUMATOLOGY, v.57, n.10, p.1721-1725, 2018
Abstract: Objective. To assess the possible effect of therapy, disease subtype and severity on H1N1 immunogenicity in patients with SSc. Methods. Ninety-two patients and 92 age- and gender-matched healthy controls received adjuvant-free influenza A/California/7/2009 (pH1N1) vaccine. Blood samples were collected immediately before and 3 weeks after vaccination to evaluate antibody responses to the H1N1 virus. Efficacy was assessed by seroprotection (SP) and seroconversion (SC) rates and the factor increase in geometric mean antibody titre. Participants received a 21-day symptom diary card and were instructed to report local and systemic adverse events. Results. SSc patients were predominantly females (91 %) and 61 % had limited SSc, 12% had severe skin involvement and 57.6% were on immunosuppressive (IS) therapy. SSc patients and controls presented comparable overall SP (P=0.20) and SC (P=0.61) rates. Further evaluation of the possible effect of disease and therapy revealed similar rates of SP and SC in patients with dcSSc vs IcSSc (SP P =0.62 and SC P = 0.66), severe vs mild/moderate skin involvement (SP P=1 and SC P = 0.45) and with vs without IS (SP P = 0.26 and SC P=0.10). The frequency of mild local and minor systemic reactions was similar in patients with dcSSC vs IcSSc (P =0.70 vs 0.32) and in those with and without severe skin involvement (P = 0.59 vs 0.28). Conclusion. The non-adjuvanted influenza H1N1 virus vaccine proved to be safe and effective, independent of SSc clinical subtype, disease severity or therapy. These latter factors do not seem to contribute to mild adverse events observed in SSc. Our data support the annual influenza vaccination recommendation for these patients.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - FM/MPE
Departamento de Pediatria - FM/MPE

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr

Artigos e Materiais de Revistas Científicas - LIM/03
LIM/03 - Laboratório de Medicina Laboratorial

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Artigos e Materiais de Revistas Científicas - LIM/36
LIM/36 - Laboratório de Pediatria Clínica


Files in This Item:
File Description SizeFormat 
art_SAMPAIO-BARROS_Pandemic_nonadjuvanted_influenza_A_H1N1_vaccine_in_a_2018.PDF
  Restricted Access
publishedVersion (English)149.62 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.